# Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

> **NCT05843253** · PHASE2 · RECRUITING · sponsor: **Nationwide Children's Hospital** · enrollment: 120 (estimated)

## Conditions studied

- High Grade Glioma
- Diffuse Intrinsic Pontine Glioma
- Anaplastic Astrocytoma
- Glioblastoma
- Glioblastoma Multiforme
- Diffuse Midline Glioma, H3 K27M-Mutant
- Metastatic Brain Tumor
- WHO Grade III Glioma
- WHO Grade IV Glioma
- Diffuse Hemispheric Glioma, H3 G34-Mutant

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Everolimus
- **DRUG:** Temozolomide (TMZ)

## Key facts

- **NCT ID:** NCT05843253
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-22
- **Primary completion:** 2029-08-31
- **Final completion:** 2034-08-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05843253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05843253, "Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05843253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*